The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted Humanigen’s marketing authorisation submission for Lenzilumab in Covid-19 for expedited Covid-related rolling review, with assessment expected to happen more quickly than a standard rolling review. According to Public Health England, despite 86% of the UK being inoculated with the first dose of the vaccine, the current seven-day hospitalisation rate was approximately 2,500, a 45% increase from the previous period.

The Russian Direct Investment Fund, an investor in the Russian Sputnik V vaccine against Covid-19, has announced the positive safety and tolerability data of the jab during a San Marino vaccination campaign in Europe. The countrywide study was conducted among San Marino individuals who received one or two doses of the vaccine between 4 March and 8 April 2021. The study revealed high tolerability for individuals aged 60 years and above, with no hospitalisations or deaths reported.

A study by Public Health England, which included more than one million people in at-risk groups, showed Covid-19 vaccines such as the Pfizer and AstraZeneca jabs to be highly effective. The study found overall vaccine effectiveness against symptomatic risk groups to be approximately 60% after one dose of either the AstraZeneca or Pfizer-BioNTech, with little variation by age. It also showed vaccine effectiveness to be 81% with AstraZeneca when people in risk groups aged between 16 to 64 years were administered two vaccine doses. Meanwhile, the Pfizer vaccine was 89% effective for people aged 65 years and older and AstraZeneca 80% effective. For the immunosuppressed, vaccine effectiveness was found to be 74% after a second dose, with similar protection to those who did not fall into a risk group.